Adrenal androgens stimulate the proliferation of breast cancer cells as direct activators of estrogen receptor α

Cancer Research

Volumn 59, Issue 19, 1999, Pages 4864-4869

  Maggiolini, Marcello ^a   Donzé, Olivier ^a   Jeannin, Elisabeth ^a   Andö, Sebastiano ^b   Picard, Didier ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b UNIVERSITY OF CALABRIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

5ALPHA ANDROSTENE 3BETA,17BETA DIOL; ANDROGEN; ANDROSTANOLONE; ANTIESTROGEN; AROMATASE INHIBITOR; ESTROGEN RECEPTOR; PRASTERONE; TESTOSTERONE; UNCLASSIFIED DRUG;

ADRENAL GLAND; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER RISK; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; NONHUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; REPORTER GENE; RISK FACTOR; TRANSACTIVATION;

ANDROGENS; ANDROSTENEDIOL; BREAST NEOPLASMS; CELL DIVISION; CLONING, MOLECULAR; DEHYDROEPIANDROSTERONE; DIHYDROTESTOSTERONE; ESTROGEN RECEPTOR ALPHA; FEMALE; GENES, REPORTER; HELA CELLS; HUMANS; LUCIFERASES; RECEPTORS, ESTROGEN; RECOMBINANT FUSION PROTEINS; SACCHAROMYCES CEREVISIAE; TESTOSTERONE; TRANSFECTION; TUMOR CELLS, CULTURED; UTERUS;

EID: 0033214658     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Hoskins, K., and Weber, B. L. The biology of breast cancer. Curr. Opin. Oncol., 6: 554-559, 1994.
2. Korach, K. S. Insights from the study of animals lacking functional estrogen receptor. Science (Washington DC), 266: 1524-1527, 1994.
3. Eisen, A., and Weber, B. L. Recent advances in breast cancer biology. Curr. Opin. Oncol., 10: 486-491, 1998.
4. Jordan, V. Designer estrogens. Sci. Am., 279: 60-67, 1998.
5. Gustafsson, J-Å. Therapeutic potential of selective estrogen receptor modulators. Curr. Opin. Chem. Biol., 2: 508-511, 1998.
6. Picard, D., Bunone, G., Liu, S. W., and Donzé, O. Steroid-independent activation of steroid receptors in mammalian and yeast cells and in breast cancer. Biochem. Soc. Trans., 25: 597-602, 1997.
7. Kalkhoven, E., Beraldi, E., Panno, M. L., De Winter, J. P., Thijssen, J. H., and Van Der Burg, B. Growth inhibition by anti-estrogens and progestins in TGF-β-resistant and -sensitive breast-tumor cells. Int. J. Cancer, 65: 682-687, 1996.
8. Cenni, B., and Picard, D. Ligand-independent activation of steroid receptors: new roles for old players. Trends Endocrinol. Metab., 10: 41-46, 1999.
9. Masamura, S., Santner, S. J., Heitjan, D. F., and Santen, R. J. Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. J. Clin. Endocrinol. Metab., 80: 2918-2925, 1995.
10. Jeng, M. H., Shupnik, M. A., Bender, T. P., Westin, E. H., Bandyopadhyay, D., Kumar, R., Masamura, S., and Santen, R. J. Estrogen receptor expression and function in long-term estrogen-deprived human breast cancer cells. Endocrinology, 139: 4164-4174, 1998.
11. Santner, S. J., Pauley, R. J., Tait, L., Kaseta, J., and Santen, R. J. Aromatase activity and expression in breast cancer and benign breast tissue stromal cells. J. Clin. Endocrinol. Metab., 82: 200-208, 1997.
12. Ekena, K., Katzenellenbogen, J. A., and Katzenellenbogen, B. S. Determinants of ligand specificity of estrogen receptor-α: estrogen versus androgen discrimination. J. Biol. Chem., 273: 693-699, 1998.
13. Kuiper, G. G., Carlsson, B., Grandien, K., Enmark, E., Haggblad, J., Nilsson, S., and Gustafsson, J. A. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β. Endocrinology, 138; 863-870, 1997.
14. Adams, J., Garcia, M., and Rochefort, H. Estrogenic effects of physiological concentrations of 5-androstene-3β,17β-diol and its metabolism in MCF7 human breast cancer cells. Cancer Res., 41: 4720-4726, 1981.
15. Poulin, R., and Labrie, F. Stimulation of cell proliferation and estrogenic response by adrenal C19-Δ5-steroids in the ZR-75-1 human breast cancer cell line. Cancer Res., 46: 4933-4937, 1986.
16. Le Bail, J. C., Marre-Fournier, F., Nicolas, J. C., and Habrioux, G. C19 steroids estrogenic activity in human breast cancer cell lines: importance of dehydroepiandrosterone sulfate at physiological plasma concentration. Steroids, 63: 678-683, 1998.
17. Le Bail, J. C., Allen, K., Nicolas, J. C., and Habrioux, G. Dehydroepiandrosterone sulfate estrogenic action at its physiological plasma concentration in human breast cancer cell lines. Anticancer Res., 18: 1683-1688, 1998.
18. Najid, A., and Habrioux, G. Biological effects of adrenal androgens on MCF-7 and BT-20 human breast cancer cells. Oncology, 47: 269-274, 1990.
19. Birrell, S. N., Bentel, J. M., Hickey, T. E., Ricciardelli, C., Weger, M. A., Horsfall, D. J., and Tilley, W. D. Androgens induce divergent proliferative responses in human breast cancer cell lines. J. Steroid Biochem. Mol. Biol., 52: 459-467, 1995.
20. Boccuzzi, G., Brignardello, E., di Monaco, M., Forte, C., Leonardi, L., and Pizzini, A. Influence of dehydroepiandrosterone and 5-en-androstene-3β,17β-diol on the growth of MCF-7 human breast cancer cells induced by 17β-estradiol. Anticancer Res., 12: 799-803, 1992.
21. Bunone, G., Briand, P-A., Miksicek, R. J., and Picard, D. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J., 15: 2174-2183, 1996.
22. Webb, P., Nguyen, P., Shinsako, J., Anderson, C., Feng, W., Nguyen, M. P., Chen, D., Huang, S. M., Subramanian, S., McKinerney, E., Katzenellenbogen, B. S., Stallcup, M. R., and Kushner, P. J. Estrogen receptor activation function 1 works by binding p160 coactivator proteins. Mol. Endocrinol., 12: 1605-1618, 1998.
23. Picard, D. Regulation of heterologous proteins by fusion to a hormone binding domain. In: D. Picard (ed.), Nuclear Receptors: A Practical Approach. Oxford, United Kingdom: Oxford University Press, 1999.
24. Seipel, K., Georgiev, O., and Schaffner, W. Different activation domains stimulate transcription from remote (enhancer) and proximal (promoter) positions. EMBO J., 11: 4961-4968, 1992.
25. Liu, J. W., and Picard, D. Bioactive steroids as contaminants of the common carbon source galactose. FEMS Microbiol. Lett., 159: 167-171, 1998.
26. Schena, M., Picard, D., and Yamamoto, K. R. Vectors for constitutive and inducible gene expression in yeast. Methods Enzymol., 194: 389-398, 1991.
27. Picard, D., Khursheed, B., Garabedian, M. J., Fortin, M. G., Lindquist, S., and Yamamoto, K. R. Reduced levels of hsp90 compromise steroid receptor action in vivo. Nature (Lond.), 348: 166-168, 1990.
28. Yocum, R. R., Hanley, S., West, R. W., Jr., and Ptashne, M. Use of lacZ fusions to delimit regulatory elements of the inducible divergent GAL1-GAL10 promoter in Saccharomyces cerevisiae. Mol. Cell. Biol., 4: 1985-1998, 1984.
29. Neff, S., Sadowski, C., and Miksicek, R. J. Mutational analysis of cysteine residues within the hormone-binding domain of the human estrogen receptor identifies mutants that are defective in both DNA-binding and subcellular distribution. Mol. Endocrinol., 8: 1215-1223, 1994.
30. Eckert, R. L., Mullick, A., Rorke, E. A., and Katzenellenbogen, B. S. Estrogen receptor synthesis and turnover in MCF-7 breast cancer cells measured by a density shift technique. Endocrinology, 114: 629-637, 1984.
31. Santagati, S., Gianazza, E., Agrati, P., Vegeto, E., Patrone, C., Pollio, G., and Maggi, A. Oligonucleotide squelching reveals the mechanism of estrogen receptor autologous down-regulation. Mol. Endocrinol., 11: 938-949, 1997.
32. Metzger, D., White, J. H., and Chambon, P. The human estrogen receptor functions in yeast. Nature (Lond.), 334: 31-36, 1988.
33. Garabedian, M. J., and Yamamoto, K. R. Genetic dissection of the signaling domain of a mammalian steroid receptor in yeast. Mol. Biol. Cell, 3: 1245-1257, 1992.
34. Kralli, A., Bohen, S. P., and Yamamoto, K. R. LEM1, an ATP-binding-cassette transporter, selectively modulates the biological potency of steroid hormones. Proc. Natl. Acad. Sci. USA, 92: 4701-4705, 1995.
35. Bruder, J. M., Sobek, L., and Oettel, M. Dehydroepiandrosterone stimulates the estrogen response element. J. Steroid Biochem. Mol. Biol., 62: 461-466, 1997.
36. Migliaccio, A., Piccolo, D., Castoria, G., Di Domenico, M., Bilancio, A., Lombardi, M., Gong, W., Beato, M., and Auricchio, F. Activation of the Src/p21ras/Erk pathway by progesterone receptor via cross-talk with estrogen receptor. EMBO J., 17: 2008-2018, 1998.
37. Sasarro, H., and Harada, N. Intratumoral aromatase in human breast, endometrial, and ovarian malignancies. Endocr. Rev., 19: 593-607, 1998.
38. Yue, W., Santner, S. J., Masamura, S., Wang, J. P., Demers, L. M., Hamilton, C., and Santen, R. J. Determinants of tissue estradiol levels and biologic responsiveness in breast tumors. Breast Cancer Res. Treat., 49: S1-S7, 1998.
39. Dorgan, J. F., Stanczyk, F. Z., Longcope, C., Stephenson, H. E., Jr., Chang, L., Miller, R., Franz, C., Falk, R. T., and Kahle, L. Relationship of serum dehydroepiandrosterone (DHEA), DHEA sulfate, and 5-androstene-3β,17β-diol to risk of breast cancer in postmenopausal women. Cancer Epidemiol. Biomark. Prev., 6: 177-181, 1997.